A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice

References

• Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2018.5904.
   Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1–15. doi:10.1158/2159-8290.CD-18-0367.
   Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093–2104. doi:10.1056/NEJMoa1801946.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2018;33:853–861.e4. doi:10.1016/j.ccell.2018.04.001.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789–1801. doi:10.1056/NEJMoa1802357.
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;379:e14. doi:10.1056/NEJMc1808251.
   PubMedGoogle Scholar
• Budczies J, Mechtersheimer G, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, Endris V, Lier A, et al. PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. Oncoimmunology. 2017;6:e1279777. doi:10.1080/2162402X.2017.1279777.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–723. doi:10.1016/j.cell.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–2092. doi:10.1056/NEJMoa1801005.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28:690–714. doi:10.1016/j.ccell.2015.10.012.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118:1991–2001. doi:10.1172/JCI35180.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59–73. doi:10.1038/nri2216.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. doi:10.1146/annurev-immunol-032712-100008.
   PubMed Web of Science ®Google Scholar
• Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691–1701. doi:10.1084/jem.20050915.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Pitt JM, Daillere R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer. 2016;16:759–773. doi:10.1038/nrc.2016.91.
   PubMed Web of Science ®Google Scholar
• Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38:729–741. doi:10.1016/j.immuni.2013.03.003.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015;21:1128–1138. doi:10.1038/nm.3944.
   PubMed Web of Science ®Google Scholar
• Bezu L, Sauvat A, Humeau J, Leduc M, Kepp O, Kroemer G. eIF2alpha phosphorylation: a hallmark of immunogenic cell death. Oncoimmunology. 2018;7:e1431089. doi:10.1080/2162402X.2018.1490854.
   PubMed Web of Science ®Google Scholar
• Stoll G, Ma Y, Yang H, Kepp O, Zitvogel L, Kroemer G. Pro-necrotic molecules impact local immunosurveillance in human breast cancer. Oncoimmunology. 2017;6:e1299302. doi:10.1080/2162402X.2017.1299302.
   PubMed Web of Science ®Google Scholar
• Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology. 2017;6:e1386829. doi:10.1080/2162402X.2017.1386829.
   PubMed Web of Science ®Google Scholar
• Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautes-Fridman C, Fucikova J, Galon J, Spisek R, et al. Trial watch: immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015;4:e1008866. doi:10.1080/2162402X.2015.1008371.
   PubMed Web of Science ®Google Scholar
• Castoldi F, Vacchelli E, Zitvogel L, Maiuri MC, Pietrocola F, Kroemer G. Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. Oncoimmunology. 2019;8:e1498285. doi:10.1080/2162402X.2018.1498285.
   PubMed Web of Science ®Google Scholar
• Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334:1573–1577. doi:10.1126/science.1208347.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15:1170–1178. doi:10.1038/nm.2028.
   PubMed Web of Science ®Google Scholar
• Marino G, Pietrocola F, Eisenberg T, Kong Y, Malik SA, Andryushkova A, Schroeder S, Pendl T, Harger A, Niso-Santano M, et al. Regulation of autophagy by cytosolic acetyl-coenzyme A. Mol Cell. 2014;53:710–725. doi:10.1016/j.molcel.2014.01.016.
   PubMed Web of Science ®Google Scholar
• Madeo F, Carmona-Gutierrez D, Hofer SJ, Kroemer G. Caloric restriction mimetics against age-associated disease: targets, mechanisms, and therapeutic potential. Cell Metab. 2019;29:592–610. doi:10.1016/j.cmet.2019.01.018.
   PubMed Web of Science ®Google Scholar
• Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell. 2016;30:147–160. doi:10.1016/j.ccell.2016.05.016.
   PubMed Web of Science ®Google Scholar
• Pietrocola F, Pol J, Vacchelli E, Baracco EE, Levesque S, Castoldi F, Maiuri MC, Madeo F, Kroemer G. Autophagy induction for the treatment of cancer. Autophagy. 2016;12:1962–1964. doi:10.1080/15548627.2016.1214778.
   PubMed Web of Science ®Google Scholar
• Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325:201–204. doi:10.1126/science.1173635.
   PubMed Web of Science ®Google Scholar
• Eisenberg T, Knauer H, Schauer A, Buttner S, Ruckenstuhl C, Carmona-Gutierrez D, Ring J, Schroeder S, Magnes C, Antonacci L, et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol. 2009;11:1305–1314. doi:10.1038/ncb1975.
   PubMed Web of Science ®Google Scholar
• Pietrocola F, Lachkar S, Enot DP, Niso-Santano M, Bravo-San Pedro JM, Sica V, Izzo V, Maiuri MC, Madeo F, Mariño G, et al. Spermidine induces autophagy by inhibiting the acetyltransferase EP300. Cell Death Differ. 2015;22:509–516. doi:10.1038/cdd.2014.215.
   PubMed Web of Science ®Google Scholar
• Eisenberg T, Abdellatif M, Schroeder S, Primessnig U, Stekovic S, Pendl T, Harger A, Schipke J, Zimmermann A, Schmidt A, et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med. 2016;22:1428–1438. doi:10.1038/nm.4222.
   PubMed Web of Science ®Google Scholar
• Balasubramanian P, Howell PR, Anderson RM. Aging and caloric restriction research: a biological perspective with translational potential. EBioMedicine. 2017;21:37–44. doi:10.1016/j.ebiom.2017.06.015.
   PubMed Web of Science ®Google Scholar
• Kiechl S, Pechlaner R, Willeit P, Notdurfter M, Paulweber B, Willeit K, Werner P, Ruckenstuhl C, Iglseder B, Weger S, et al. Higher spermidine intake is linked to lower mortality: a prospective population-based study. Am J Clin Nutr. 2018;108:371–380. doi:10.1093/ajcn/nqy102.
   PubMed Web of Science ®Google Scholar
• Redman LM, Smith SR, Burton JH, Martin CK, Il’yasova D, Ravussin E. Metabolic slowing and reduced oxidative damage with sustained caloric restriction support the rate of living and oxidative damage theories of aging. Cell Metab. 2018;27:805–15 e4. doi:10.1016/j.cmet.2018.02.019.
   PubMed Web of Science ®Google Scholar
• Pifferi F, Terrien J, Marchal J, Dal-Pan A, Djelti F, Hardy I, Limbani V, Steinberg J, Zengini E, Warsame K, et al. Caloric restriction increases lifespan but affects brain integrity in grey mouse lemur primates. Commun Biol. 2018;1:30. doi:10.1038/s42003-018-0052-4.
   PubMed Web of Science ®Google Scholar
• Lope V, Martin M, Castello A, Ruiz A, AM C, JM B-C, Antolín S, Ramos-Vázquez M, García-Sáenz JÁ, Muñoz M, et al. Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. Sci Rep. 2019;9:3904. doi:10.1038/s41598-019-39346-4.
   PubMed Web of Science ®Google Scholar
• Levesque S, Pol JG, Ferrere G, Galluzzi L, Zitvogel L, Kroemer G. Trial watch: dietary interventions for cancer therapy. Oncoimmunology. 2019;8:1591878. doi:10.1080/2162402X.2019.1591878.
   PubMed Web of Science ®Google Scholar
• Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L. Trial watch: immunostimulatory monoclonal antibodies for oncological indications. Oncoimmunology. 2017;6:e1371896. doi:10.1080/2162402X.2017.1371896.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, et al. Trial watch: immune checkpoint blockers for cancer therapy. Oncoimmunology. 2017;6:e1373237. doi:10.1080/2162402X.2017.1373237.
   PubMed Web of Science ®Google Scholar
• Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48:417–433. doi:10.1016/j.immuni.2018.03.007.
   PubMed Web of Science ®Google Scholar
• Yan Y, Kumar AB, Finnes H, Markovic SN, Park S, Dronca RS, Dong H. Combining immune checkpoint inhibitors with conventional cancer therapy. Front Immunol. 2018;9:1739. doi:10.3389/fimmu.2018.01739.
   PubMed Web of Science ®Google Scholar
• Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier-Colame V, Newton A, Redouane Y, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44:343–354. doi:10.1016/j.immuni.2015.11.024.
   PubMed Web of Science ®Google Scholar
• Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30:219–235. doi:10.1093/annonc/mdy551.
   PubMed Web of Science ®Google Scholar
• Zhou J, Yang T, Liu L, Lu B. Chemotherapy oxaliplatin sensitizes prostate cancer to immune checkpoint blockade therapies via stimulating tumor immunogenicity. Mol Med Rep. 2017;16:2868–2874. doi:10.3892/mmr.2017.6908.
   PubMed Web of Science ®Google Scholar
• Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004;63:S15–8. doi:10.1212/wnl.63.12_suppl_6.s15.
   PubMed Web of Science ®Google Scholar
• Di Biase S, Lee C, Brandhorst S, Manes B, Buono R, Cheng C-W, Cacciottolo M, Martin-Montalvo A, de Cabo R, Wei M, et al. Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity. Cancer Cell. 2016;30:136–146. doi:10.1016/j.ccell.2016.06.005.
   PubMed Web of Science ®Google Scholar
• Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 1992;52:194–201.
   PubMed Web of Science ®Google Scholar
• Bloy N, Garcia P, Laumont CM, Pitt JM, Sistigu A, Stoll G, Yamazaki T, Bonneil E, Buqué A, Humeau J, et al. Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunol Rev. 2017;280:165–174. doi:10.1111/imr.12582.
   PubMed Web of Science ®Google Scholar
• Humeau J, Lévesque S, Kroemer G, Pol JG. Gold standard assessment of immunogenic cell death in oncological mouse models. Methods Mol Biol. 2019;1884:297–315. doi:10.1007/978-1-4939-8885-3_21.
   PubMedGoogle Scholar
• Bezu L, Gomes-de-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O, Kroemer G. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:187.
   PubMed Web of Science ®Google Scholar
• Puleston DJ, Zhang H, Powell TJ, Lipina E, Sims S, Panse I, Watson AS, Cerundolo V, Townsend AR, Klenerman P, et al. Autophagy is a critical regulator of memory CD8+ T cell formation. Elife. 2014;3. doi:10.7554/eLife.03706.
   PubMed Web of Science ®Google Scholar
• Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, Apetoh L. Trial watch: adoptively transferred cells for anticancer immunotherapy. Oncoimmunology. 2017;6:e1363139. doi:10.1080/2162402X.2017.1363139.
   PubMed Web of Science ®Google Scholar
• Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, Kroemer G, Galluzzi L, Garg AD. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology. 2019;1–21. doi:10.1080/2162402X.2019.1638212.
   PubMed Web of Science ®Google Scholar
• Pol JG, Levesque S, Workenhe ST, Gujar S, Le Boeuf FClements DR, et al. Trial watch: oncolytic viro-immunotherapy of hematologic and solid tumors. Oncoimmunology. 2018;7:e1503032.
   PubMed Web of Science ®Google Scholar
• Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, et al. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic maraba virus currently in first-in-human trials. Oncoimmunology. 2019;8:e1512329. doi:10.1080/2162402X.2018.1512329.
   PubMed Web of Science ®Google Scholar
• Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J, Breitbach CJ, Diallo J-S, et al. Development and applications of oncolytic maraba virus vaccines. Oncolytic Virother. 2018;7:117–128. doi:10.2147/OV.S154494.
   PubMed Web of Science ®Google Scholar
• Gujar S, Pol JG, Kroemer G. Heating It Up: Oncolytic Viruses Make Tumors 'Hot' and Suitable for Checkpoint Blockade Immunotherapies. Oncoimmunology 2018; 7:e1442169.
   Google Scholar
• Pierini S, Perales-Linares R, Uribe-Herranz M, Pol JG, Zitvogel L, Kroemer G, Facciabene A, Galluzzi L. Trial watch: DNA-based vaccines for oncological indications. Oncoimmunology. 2017;6:e1398878. doi:10.1080/2162402X.2017.1398878.
   PubMed Web of Science ®Google Scholar
• Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. doi:10.1093/bioinformatics/bts635.
   PubMed Web of Science ®Google Scholar
• Noli L, Capalbo A, Ogilvie C, Khalaf Y, Ilic D. Discordant growth of monozygotic twins starts at the blastocyst stage: a case study. Stem Cell Rep. 2015;5:946–953. doi:10.1016/j.stemcr.2015.10.006.
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi:10.1186/s13059-014-0550-8.
   PubMed Web of Science ®Google Scholar
• Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57. doi:10.1038/nprot.2008.211.
   PubMed Web of Science ®Google Scholar
• Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1–13. doi:10.1093/nar/gkn923.
   PubMed Web of Science ®Google Scholar
• Enot DP, Vacchelli E, Jacquelot N, Zitvogel L, Kroemer G. Tumgrowth: An Open-access Web Tool for The Statistical Analysis of Tumor Growth Curves. Oncoimmunology. 2018:7:e1462431.
   Google Scholar